BVS — Bioventus Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1665988 ·
Last close
$10.60
Market Cap
$725.83M
52W High
$15.89
52W Low
$6.47
ADV30
578,703
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 142,442,000 | 97,128,000 | 9,700,000 | 5,987,000 | 673,430,000 | 30,709,000 | 381,556,000 |
| Jun 2026 | 153,208,000 | 105,666,000 | 18,712,000 | 33,441,000 | 673,346,000 | 29,457,000 | 395,934,000 |
| Mar 2026 | 132,089,000 | 90,769,000 | 8,870,000 | 3,113,000 | 650,539,000 | 35,846,000 | 416,274,000 |
| Dec 2025 | 157,900,000 | 108,782,000 | 21,721,000 | 14,755,000 | 683,559,000 | 51,238,000 | 455,112,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$87,433,000
Investing CF
$-5,448,000
Financing CF
$-92,606,000
CapEx
$-2,448,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.80
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-292,388,000
Inventory
$83,096,000
Receivables
$138,228,000
ST Investments
—
EBIT TTM
$57,584,000
Pretax Income TTM
$40,126,000
Interest Exp TTM
$17,458,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$585,638,976
EBITDA
$77,493,000
Free Cash Flow
$55,570,500
Enterprise Value
$989,004,480
Total Cash
$33,032,000
Total Debt
$244,150,000
Shares Out
68,474,219
Trailing EPS
$0.81
Book Value
$3.51
ROE
25.8%
ROA
5.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 568,087,000 | 56,291,000 | 22,732,000 | 683,559,000 | 455,112,000 | 184,105,000 | 74,673,000 |
| Dec 2024 | 573,280,000 | 22,825,000 | -36,125,000 | 727,956,000 | 542,352,000 | 147,940,000 | 38,795,000 |
| Dec 2023 | 512,345,000 | 2,026,000 | -156,230,000 | 810,910,000 | 589,792,000 | 173,591,000 | 15,344,000 |
| Dec 2022 | 512,117,000 | -34,656,000 | -158,704,000 | 1,372,649,000 | 960,427,000 | 325,238,000 | -13,537,000 |
TTM Snapshot
Revenues TTM
$581,848,000
NetIncome TTM
$54,464,000
OpCashFlow TTM
—
Assets (Latest)
$673,346,000
Forward EPS
$0.91
Max Pain — expiry 2027-01-15
max pain strike: $7.50 · spot: $10.62 · call oi: 1,629 · put oi: 24
Expected Move to 2027-01-15:
±$2.31
(21.75%) —
implied range
$8.31 –
$12.93
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INMD | InMode Ltd. | $743.47M | $12.92 | — |
| STVN | Stevanato Group S.p.A. | $759.94M | $15.25 | — |
| DCTH | DELCATH SYSTEMS, INC. | $673.84M | $19.37 | — |
| BBNX | Beta Bionics, Inc. | $800.28M | $14.72 | — |
| KIDS | ORTHOPEDIATRICS CORP | $820.13M | $31.41 | — |
News headlines (Yahoo Finance, 1h cache)
Bioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue Outlook
2026-11-04 04:37 · Yahoo
Bioventus Inc (BVS) Q3 2026 Earnings Call Highlights: Solid Pain and Ultrasonics Growth Offset ...
2026-11-03 07:04 · Yahoo
Bioventus (BVS) Q3 2026 Earnings Call Transcript
2026-11-03 04:28 · Yahoo
Bioventus Q3 Earnings Call Highlights
2026-11-02 23:13 · Yahoo
Bioventus: Q3 Earnings Snapshot
2026-11-02 23:01 · Yahoo
Bioventus (BVS) Matches Q3 Earnings Estimates
2026-11-02 21:55 · Yahoo
Bioventus Reports Third Quarter Financial Results
2026-11-02 21:05 · Yahoo
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
2026-10-27 11:00 · Yahoo
Bioventus (BVS) Q2 2026 Earnings Call Transcript
2026-08-13 13:17 · Yahoo
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
2026-08-10 20:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.